Genitourinary Cancers | Specialty

Management of Oncology Care in Urology Practices

August 10th 2012

Physician Extenders in Urology Practices, Part II

August 10th 2012

Studies Support Efficacy of Axitinib as First- and Second-Line Kidney Cancer Treatment

July 30th 2012

Research presented at ASCO 2012 demonstrated the efficacy of axitinib (Inlyta) as both a first- and second-line treatment in patients with metastatic renal cell carcinoma.

Tivozanib Improves PFS Versus Sorafenib in Patients With Renal Cell Carcinoma

July 24th 2012

Tivozanib increased progression-free survival and objective response rate in patients with renal cell carcinoma compared with sorafenib.

The Urology Group: Balancing Expansion With Commitment to the Community

July 13th 2012

In tough economic times when many medical practices have scaled back or even shut down, The Urology Group has flourished.

Dr. Concepcion Discusses Urologists Treating Cancer

July 12th 2012

Dr. Raoul Concepcion, from Urology Associates, PC, Discusses Urologists Treating Cancer.

Bone Health Programs in Urology Practices Deliver Continuity of Care

July 12th 2012

Spurred by the desire to provide the full spectrum of care to prostate cancer patients, urologists across the country have begun to integrate bone health clinics into their practices.

EHRs in the Urology Office

July 11th 2012

The implementation of electronic health records to replace paper charts in urology practices is a recent phenomenon that is picking up some serious momentum.

The Therapeutic Landscape of Metastatic Renal Cell Carcinoma in 2012

July 9th 2012

In the last seven years, since the introduction of the targeted therapies, remarkable progress has transpired that has transformed the therapeutic landscape for metastatic renal cell carcinoma.

Case-Based Discussion: Sequencing Prostate Cancer Therapy

July 3rd 2012

Case-based discussion on sequencing prostate cancer therapies for a 72-year-old man with a metastatic adenocarcinoma with small-cell components, a PSA score of 80, and a Gleason score of 10.

High Points and Hurdles: Immunotherapy Moves Forward

June 27th 2012

Immunotherapy is maintaining its momentum in clinical development programs, with explorations under way in many tumor types, including breast and lung cancers previously considered poor candidates for such modalities.

NSAIDs and Statins Have No Impact on Renal Cell Carcinoma Risk

June 26th 2012

New data appears to undercut prior research by suggesting that neither NSAIDs nor statins influence the development of renal cell carcinoma.

Dr. Topalian on the PD-1 Immunotherapy BMS-936558

June 22nd 2012

Dr. Suzanne Topalian, from the Johns Hopkins University School of Medicine, on the PD-1 Targeted Immunotherapy BMS-936558.

Urology Under Attack

June 21st 2012

As we head into the sweltering days of summer, physicians-and urologists in particular-face a series of challenges that can potentially impact the way we practice and how we manage our patients.

Dr. Escudier on Patients Preferring Pazopanib for mRCC

June 15th 2012

Dr. Bernard Escudier, from the Institut Gustave Roussy, on Patients Preferring Pazopanib for Metastatic Renal Cell Carcinoma.

Dr. Concepcion on Bladder Cancer Treatment and Costs

June 14th 2012

Dr. Raoul Concepcion, from the Urology Associates, PC, Nashville, TN, on Bladder Cancer Treatment and Costs.

Dr. Brahmer on the PD-1 Immunotherapy BMS-936558

June 7th 2012

Dr. Julie Brahmer, from the Sidney Kimmel Comprehensive Cancer Center, on the PD-1 Immunotherapy BMS-93655 Clinical Trial

Dr. Topalian on the PD-1 Targeted Therapy BMS-936558

June 2nd 2012

Dr. Suzanne Topalian, from Johns Hopkins University School of Medicine, on the PD-1 Targeted Therapy BMS-936558

Patients With Metastatic Kidney Cancer Prefer Pazopanib Over Sunitinib, Study Shows

June 2nd 2012

Study finds that more than two-thirds of patients with metastatic kidney cancer prefer pazopanib over another FDA-approved treatment, sunitinib.

Maximum 12-Month Follow-Up Suffices in More than Half of Men with Surgically-Treated Invasive Penile Cancer

May 16th 2012

In men with primary squamous cell carcinoma of the penis who have undergone surgery that removed all glanular epithelium a maximum 12-month follow-up period is recommended.